company background image
SFA logo

Sopharma AD BUL:SFA Stock Report

Last Price

лв5.96

Market Cap

лв1.1b

7D

-3.9%

1Y

7.2%

Updated

13 Jun, 2024

Data

Company Financials +

SFA Stock Overview

Researches and develops, produces, and trades in medicinal substances, finished drug forms, infusion medicine, and plastic medical disposable products for human and veterinary medicine, and food supplements in Bulgaria and internationally.

SFA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance3/6
Financial Health5/6
Dividends3/6

Sopharma AD Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sopharma AD
Historical stock prices
Current Share Priceлв5.96
52 Week Highлв7.76
52 Week Lowлв5.20
Beta-0.037
1 Month Change-0.67%
3 Month Change-5.70%
1 Year Change7.19%
3 Year Change63.74%
5 Year Change74.78%
Change since IPO-3.67%

Recent News & Updates

Here's Why Sopharma AD (BUL:SFA) Can Manage Its Debt Responsibly

Jun 02
Here's Why Sopharma AD (BUL:SFA) Can Manage Its Debt Responsibly

Recent updates

Here's Why Sopharma AD (BUL:SFA) Can Manage Its Debt Responsibly

Jun 02
Here's Why Sopharma AD (BUL:SFA) Can Manage Its Debt Responsibly

Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance Sheet

Apr 09
Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance Sheet

Here's Why We Think Sopharma AD (BUL:3JR) Is Well Worth Watching

Feb 20
Here's Why We Think Sopharma AD (BUL:3JR) Is Well Worth Watching

How Many Sopharma AD (BUL:3JR) Shares Do Institutions Own?

Feb 05
How Many Sopharma AD (BUL:3JR) Shares Do Institutions Own?

Should You Rely On Sopharma AD's (BUL:3JR) Earnings Growth?

Jan 22
Should You Rely On Sopharma AD's (BUL:3JR) Earnings Growth?

Sopharma AD (BUL:3JR) Has A Somewhat Strained Balance Sheet

Jan 06
Sopharma AD (BUL:3JR) Has A Somewhat Strained Balance Sheet

Sopharma AD (BUL:3JR) Share Prices Have Dropped 25% In The Last Three Years

Dec 22
Sopharma AD (BUL:3JR) Share Prices Have Dropped 25% In The Last Three Years

Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Dec 07
Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Are Investors Undervaluing Sopharma AD (BUL:3JR) By 29%?

Nov 19
Are Investors Undervaluing Sopharma AD (BUL:3JR) By 29%?

Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Jul 07
Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?

Shareholder Returns

SFABG PharmaceuticalsBG Market
7D-3.9%2.3%-0.4%
1Y7.2%20.3%18.1%

Return vs Industry: SFA underperformed the BG Pharmaceuticals industry which returned 20.3% over the past year.

Return vs Market: SFA underperformed the BG Market which returned 18.1% over the past year.

Price Volatility

Is SFA's price volatile compared to industry and market?
SFA volatility
SFA Average Weekly Movement2.6%
Pharmaceuticals Industry Average Movement5.1%
Market Average Movement5.0%
10% most volatile stocks in BG Market8.1%
10% least volatile stocks in BG Market1.9%

Stable Share Price: SFA has not had significant price volatility in the past 3 months.

Volatility Over Time: SFA's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19334,721Ognian Donevwww.sopharmagroup.com

Sopharma AD researches and develops, produces, and trades in medicinal substances, finished drug forms, infusion medicine, and plastic medical disposable products for human and veterinary medicine, and food supplements in Bulgaria and internationally. It offers products in various therapeutic areas, such as cardiology, gastroenterology, pain management, cough and cold, immunology and dermatology, respiratory and asthma, neurology and psychiatry, urology, and gynecology. The company’s products comprise Carsil to treat gastroenterological disorders; Tempalgin, an analgesic; Tabex, a plant-based drug used for smoking secession; Tribestan, a plant-based drug used for stimulation of the reproductive system; Broncholytin, which is used to suppress cough; Analgin, a generic analgesic; Nivalin, a plant-based product used for diseases of the peripheral nervous system; and Methylprednisolon, a general medicine for cases of severe allergies and life-threatening conditions.

Sopharma AD Fundamentals Summary

How do Sopharma AD's earnings and revenue compare to its market cap?
SFA fundamental statistics
Market capлв1.07b
Earnings (TTM)лв92.66m
Revenue (TTM)лв1.93b

11.5x

P/E Ratio

0.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SFA income statement (TTM)
Revenueлв1.93b
Cost of Revenueлв1.51b
Gross Profitлв426.62m
Other Expensesлв333.96m
Earningsлв92.66m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Jan 30, 2025

Earnings per share (EPS)0.52
Gross Margin22.08%
Net Profit Margin4.80%
Debt/Equity Ratio36.3%

How did SFA perform over the long term?

See historical performance and comparison

Dividends

15.1%

Current Dividend Yield

225%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.